Copy Link Print Information

Lenzilumab

(別名: KB 003)
2 Cited Publications
カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.64%
  • CAS 番号: 1229575-09-0
  • 分子量:145.72 kDa
  • 保管条件:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Lenzilumab Chemical Structure
    Lenzilumab 構造式
CAS 番号: 1229575-09-0
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Lenzilumab おすすめ製品:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 Lenzilumab

More
Customer Validation & Images
Others
  • Others
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.

  • 1/16

    Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.

  • 1/16

    Lenzilumab purchased from MedChemExpress. Usage Cited in: Arthritis Res Ther. 2025 Sep 26;27(1):180. [Abstract]

    Customer Validation
     Extracellular acidification rate (ECAR) measured by Seahorse assay in HMDMs exposed to RA serum with or without IL-1RN, infliximab, or lenzilumab (10 µg/mL).

  • Lenzilumab Chemical Structure
    1/16
  • Lenzilumab
  • Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.
  • Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.